nach oben

Rheumatology International

Erschienen in:

01.09.2009 | Case Report

Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab

verfasst von: Valdeŕilio Feijó Azevedo, C. Parchen, S. A. Coelho, D. C. Lacerda, C. G. Hirth

Erschienen in: Rheumatology International | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

We present a rare case of tuberculous myositis in a 36-year-old man with long-standing ankylosing spondyltis treated with adalimumab. We review the association between antitumor necrosis factor therapy and tuberculous myositis. Our case illustrates that the index of suspicion of tuberculosis in these patients, even with atypical clinical features, must be very high and emphasizes that this rare infection may occur even with negative tuberculosis screening before therapy was started.

Braun J, Landewe R, Hermann KG et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652. doi:10.1002/art.21790 PubMedCrossRef

Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230–3236. doi:10.1002/art.11325 PubMedCrossRef

van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136–2146. doi:10.1002/art.21913 PubMedCrossRef

Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452. doi:10.1136/ard.2005.041137 PubMedCrossRef

Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127. doi:10.1002/art.11137 PubMedCrossRef

Sieper J, Rudwaleit M, Braun J (2007) Adalimumab for the treatment of ankylosing spondylitis. Expert Opin Pharmacother 8(6):831–838. doi:10.1517/14656566.8.6.831 PubMedCrossRef

Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65(7):889–894. doi:10.1136/ard.2005.043166 PubMedCrossRef

Rojas-Villarraga A, Agudelo CA, Pineda-Tamayo R, Porras A, Matute G, Anaya JM (2007) Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile? Biomedica (Bogota) 27(2):159–171

Enarson DA, Fujii M, Nakielna EM, Grzybowski S (1979) Bone and joint tuberculosis: a continuing problem. Can Med Assoc J 120:139–145PubMed

10.

Wang JY, Lee LN, Hsueh PR, Shih JY, Chang YL, Yang PC, Luh KT (2003) Tuberculous myositis: a rare but existing clinical entity. Rheumatology (Oxford) 42(7):836–840

11.

Puttick MPE, Stein HB, Chan RMT, Elwood RK, How AR, Reid GD (1995) Soft tissue tuberculosis: a series of 11 cases. J Rheumatol 22:1321–1325PubMed

12.

Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-de la Villa F (2007) Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 26(3):452–453. doi:10.1007/s10067-005-0164-3 PubMedCrossRef

13.

Efde MN, Houtman PM, Spoorenberg JP, Jansen TL (2005) Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab)treatment. Neth J Med 63(3):112–114PubMed

14.

Lertxundi U, Mayo J, García M, Ruiz B, Aguirre C (2005) Tuberculosis miliar tras tratamiento con adalimumab. Farm Hosp 29(5):343–347CrossRef

15.

Wang WY, Lin FC, Tsao TY, Lu JJ (2007) Tuberculous myositis: an unusual presentation of extrapulmonary tuberculosis. J Microbiol Immunol Infect 40(1):79–82PubMed

16.

Bonomo RA, Graham R, Makley JT, Petersilge CA (1995) Tuberculous pyomyositis: an unusual presentation of disseminated Mycobacterium tuberculosis infection. Clin Infect Dis 20:1576–1577PubMed

17.

FitzGerald R, Hutchinson CE (1992) Tuberculosis of the ribs: computed tomographic findings. Br J Radiol 65:822–824PubMedCrossRef

18.

Johnson DW, Herzig KA (2000) Isolated tuberculous pyomyositis in a renal transplant patient. Nephrol Dial Transplant 15:743. doi:10.1093/ndt/15.5.743 PubMedCrossRef

19.

Gahlaut DS, Kedav N, Sikka KK, Singh KN, Samuel KC (1973) Generalised skeletal muscle tuberculosis. J Indian Med Assoc 61:92–93PubMed

Titel: Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab
verfasst von: Valdeŕilio Feijó Azevedo
C. Parchen
S. A. Coelho
D. C. Lacerda
C. G. Hirth
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 11/2009
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0837-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2009

Borrelial fasciitis: as yet insufficient proof for a distinct entity

Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation

The many faces of sarcoidosis: asymptomatic muscle mass mimicking giant-cell tumor

Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1,584 cases

An unusual central nervous system involvement in rheumatoid arthritis: combination of pachymeningitis and cerebral vasculitis

Genetic polymorphisms of interleukin-1β (−511C/T) and interleukin-1 receptor antagonist (86-bpVNTR) in susceptibility to knee osteoarthritis in a Chinese Han population

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin